Dr. Fraunfelder has received consulting fees (less than $10,000 each) from Novartis and Eli Lilly. Dr. Rosenbaum has received consulting fees (less than $10,000) from Abbott Laboratories. Oregon Health and Science University received clinical trial support from Centocor to study infliximab as a uveitis treatment in a prospective trial that has been completed; the university is in negotiations with Abbott Laboratories regarding clinical trial support for a trial to study adalimumab as a uveitis treatment.
Do tumor necrosis factor inhibitors cause uveitis? A registry-based study
Article first published online: 28 SEP 2007
Copyright © 2007 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 56, Issue 10, pages 3248–3252, October 2007
How to Cite
Lim, L. L., Fraunfelder, F. W. and Rosenbaum, J. T. (2007), Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis & Rheumatism, 56: 3248–3252. doi: 10.1002/art.22918
- Issue published online: 28 SEP 2007
- Article first published online: 28 SEP 2007
- Manuscript Accepted: 22 JUN 2007
- Manuscript Received: 14 FEB 2007
- Funds from Research to Prevent Blindness
- Stan and Madelle Rosenfeld Family Trust
- Senior Research Fellow at the Centre for Eye Research
- Funds from the Crock and Annemarie Mankiewicz-Zelkin Fellowships
Population-based studies of patients with ankylosing spondylitis indicate that tumor necrosis factor (TNF) inhibitors prevent uveitis. Paradoxically, anecdotal reports implicate etanercept as a cause of uveitis. Therefore, using the information from 2 drug events databases, the purpose of this study was to assess reported cases of uveitis associated with the use of TNF inhibitors.
Uveitis cases occurring in the US associated with etanercept, infliximab, or adalimumab therapy that were reported to 2 spontaneous reporting databases prior to January 1, 2006 were reviewed.
Overall, there were 43 cases of uveitis associated with etanercept, 14 associated with infliximab, and 2 associated with adalimumab. After normalizing for the estimated number of patients treated with each medication, etanercept was associated with a greater number of uveitis cases than infliximab (P < 0.001) and adalimumab (P < 0.01), while no such association was found between adalimumab and infliximab (P > 0.5). Using a priori criteria to avoid including patients whose underlying disease was associated with uveitis, 20 cases associated with etanercept, 4 cases associated with infliximab, and 2 cases associated with adalimumab were identified. A repeat analysis again revealed a greater number of uveitis cases associated with etanercept (P < 0.001 versus infliximab).
Etanercept therapy is associated with a significantly greater number of reported uveitis cases in comparison with infliximab and adalimumab in 2 medication side effect registries. These results are consistent with previous studies and suggest that this relationship is drug specific and not related to TNF inhibitors as a whole. However, our findings do not support the use of infliximab over etanercept; rather, if a patient develops uveitis during etanercept therapy, then a change to infliximab may be warranted.